Region Skane Skanes Universitetssjukhus

Diseases [C] – Bacterial Infections and Mycoses [C01]

At Region Skane Skanes Universitetssjukhus the infection unit is conducting studies that compare standard antibiotics with newer agents to improve outcomes for patients with serious bacterial infections such as Staphylococcus aureus bacteraemia. A parallel trial investigates how immunizations perform in individuals receiving disease‑modifying treatments for rheumatic conditions.

Comparison of penicillin‑susceptible versus cloxacillin therapy
Evaluation of vaccine immunogenicity in inflammatory rheumatic disease
Assessment of antimicrobial stewardship strategies

These efforts aim to optimize treatment effectiveness while reducing resistance and enhancing patient safety.

Diseases [C] – Cardiovascular Diseases [C14]

Research in the cardiovascular field focuses on preventing thrombotic events and managing heart failure. Trials assess apixaban for stroke prevention in patients with atrial fibrillation and chronic kidney disease, and explore the impact of vericiguat on cardiac biomarkers in pediatric heart failure.

Apixaban versus no anticoagulation in atrial fibrillation with CKD
Vericiguat effect on NT‑proBNP levels
Therapeutic strategies for takotsubo syndrome

The overarching goal is to reduce cardiovascular mortality and improve quality of life for high‑risk patients.

Diseases [C] – Digestive System Diseases [C06]

The department is evaluating novel treatment regimens for upper gastrointestinal malignancies. A key study compares definitive chemoradiotherapy with surgery‑guided approaches for locally advanced esophageal squamous cell carcinoma, while another trial investigates targeted therapy in gastrointestinal stromal tumors.

Definitive chemoradiotherapy versus surgery in esophageal SCC
Combination of sunitinib with investigational agents in GIST
Biomarker‑driven therapy selection for gastrointestinal cancers

These investigations aim to increase survival rates and preserve organ function for patients with digestive system cancers.

Diseases [C] – Eye Diseases [C11]

A pediatric ophthalmology trial tests whether topical dexamethasone eye drops can reduce the need for conventional laser treatment in infants at risk for retinopathy of prematurity. The study seeks to improve visual outcomes while minimizing invasive procedures.

Topical dexamethasone versus placebo in ROP
Assessment of visual acuity and retinal vascularization
Safety monitoring for ocular side effects

Successful results could change the standard of care for premature infants worldwide.

Diseases [C] – Female Urogenital Diseases and Pregnancy Complications [C13]

Clinical work includes a trial of metformin to prolong gestation in pregnancies complicated by early‑onset pre‑eclampsia. The study evaluates maternal and neonatal outcomes when metformin is added to expectant management.

Metformin versus placebo for pre‑eclampsia
Gestational age at delivery and neonatal health
Maternal safety and blood pressure control

The aim is to reduce preterm birth rates and improve long‑term health for both mother and child.

Diseases [C] – Hemic and Lymphatic Diseases [C15]

A broad spectrum of hematologic malignancies is under investigation, including acute leukemias, myelodysplastic syndromes, and various lymphomas. Studies evaluate novel immunotherapies, targeted agents, and stem‑cell transplantation to boost remission rates.

Immunotherapy for infant acute lymphoblastic leukemia
FL‑T3 inhibitor gilteritinib versus midostaurin in AML
CAR‑T cell therapy in rare B‑cell malignancies
Combination venetoclax and obinutuzumab in CLL

These efforts strive to increase cure rates and provide durable disease control across blood cancers.

Diseases [C] – Immune System Diseases [C20]

Investigations target autoimmune conditions such as systemic sclerosis and anti‑GBM antibody disease. Trials compare hematopoietic stem‑cell transplantation with conventional immunosuppression and assess novel proteases for rapid antibody removal.

HSCT versus immunosuppressive drugs in early diffuse systemic sclerosis
Imlifidase plus standard care for Goodpasture disease
Vaccination response in patients on immunosuppressive therapy

The purpose is to improve organ preservation, reduce disease‑related mortality, and enhance quality of life.

Diseases [C] – Musculoskeletal Diseases [C05]

Rheumatology research includes trials of biologic and small‑molecule agents for conditions like rheumatoid arthritis, psoriatic arthritis, and systemic vasculitis. The focus is on achieving disease remission while minimizing adverse effects.

New Janus kinase inhibitor versus existing biologic in RA
Combination therapy for psoriatic arthritis
Impact of immunomodulators on vaccine efficacy

Outcomes aim to provide more personalized and safer treatment pathways for musculoskeletal patients.

Diseases [C] – Neoplasms [C04]

Oncology studies span solid tumors and hematologic cancers. Trials assess checkpoint inhibitors combined with targeted agents in melanoma, evaluate novel therapies for prostate cancer, and explore precision medicine for high‑mutational‑burden tumors.

PD‑1 inhibitor plus relatlimab in metastatic melanoma
HRR‑deficient tumor response to PARP inhibition
Radioligand therapy in advanced prostate cancer
Combination immunotherapy in relapsed Hodgkin lymphoma

The overarching aim is to extend survival and achieve durable responses across diverse cancer types.

Diseases [C] – Nervous System Diseases [C10]

Neurology research includes a trial of Montelukast as a disease‑modifying therapy for mild‑to‑moderate Parkinson’s disease in patients carrying GBA1 mutations. The study measures motor progression using standardized rating scales.

Montelukast efficacy on motor symptoms in GBA‑PD
Safety monitoring for respiratory side effects
Biomarker analysis of neuroinflammation

Findings could introduce a repurposed oral medication to slow disease progression.

Diseases [C] – Nutritional and Metabolic Diseases [C18]

Metabolic studies focus on improving glycaemic control in type 2 diabetes. A head‑to‑head comparison of a novel dual‑agonist peptide with established GLP‑1 therapy evaluates changes in HbA1c and body weight.

CagriSema versus semaglutide on glucose lowering
Impact on weight reduction and cardiovascular risk markers
Safety profile regarding gastrointestinal events

The goal is to identify more effective options for patients struggling to achieve metabolic targets.

Diseases [C] – Respiratory Tract Diseases [C08]

Pediatric pulmonary research evaluates the addition of selexipag to standard therapy for children with pulmonary arterial hypertension. The trial measures time to clinical worsening and functional class improvement.

Selexipag versus placebo in pediatric PAH
Assessment of exercise capacity and hemodynamics
Safety monitoring for liver enzyme alterations

Success could expand therapeutic options for a disease with limited pediatric treatments.

Diseases [C] – Virus Diseases [C02]

Viral disease investigations include immunogenicity studies of the herpes‑zoster vaccine in patients with inflammatory rheumatic disorders, aiming to determine how disease‑modifying drugs influence vaccine response.

Shingrix efficacy in rheumatoid arthritis on biologics
Serologic response comparison across treatment groups
Adverse event surveillance post‑vaccination

These data will guide vaccination strategies for immunocompromised populations.

Health Care [N] – Environment and Public Health [N06]

Public‑health–oriented projects assess infection‑control measures and vaccination uptake within the hospital and surrounding community. One study tracks long‑term safety of a radioligand therapy for prostate cancer, providing population‑level safety data.

Long‑term safety monitoring of lutetium‑177 therapy
Evaluation of antimicrobial stewardship outcomes
Community vaccination coverage in patients with rheumatic disease

The intent is to protect both individual patients and the wider public from preventable health threats.

Psychiatry and Psychology [F] – Mental Disorders [F03]

Mental‑health research includes a double‑blind trial of two dosage regimens of COMP360 in adults with treatment‑resistant depression. The primary endpoint is improvement in depressive symptoms after six weeks.